ClearSight was founded to develop a novel intraocular lens based on proprietary technology. The company’s strategy is to focus on introducing a single product to address a specific need in ophthalmology. Presbyopia is a vision condition in which a patient loses the ability to focus on close objects. The exit strategy is based on an acquisition through a structured deal at Phase 1 clinical trials. Seed funding provided by a Colorado state grant.